Growing number of pts undergo radiotherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 12
Volume 19
Issue 12

The number of patients in the U.S. treated with radiation has increased at an average annual rate of about 7% between 2007 and 2009, according to the “2010 Radiation Therapy Market Summary Report” by IMV. Breast, prostate, and lung cancers continue to be the cancer types treated most frequently with radiation.

The number of patients in the U.S. treated with radiation has increased at an average annual rate of about 7% between 2007 and 2009, according to the “2010 Radiation Therapy Market Summary Report” by IMV. Breast, prostate, and lung cancers continue to be the cancer types treated most frequently with radiation.

An estimated 1.1 million patients were treated in 2009 with radiation at 2,170 radiation therapy locations in the U.S. Compared to 2007, this represents a 15% increase from just over 954,000 patients, the report stated.

Over one-third of the sites surveyed reported that they are planning to purchase external-beam therapy units in the next three years, according to the report. Also, of the treatment planning systems installed, over half of the hardware or server technology was upgraded between 2008 and 2009.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
Related Content